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Classic diseases revisited
Haemophilia
Summary
Although the nature ofhaemophi-
lia has been understood for thou-
sands of years, knowledge of its
molecular genetics is recent.
These X-linked bleeding disorders
have diverse underlying DNA de-
fects and, in 1992, DNA inversion
within the X chromosome was
found to explain half of the most
serious cases of haemophilia A.
The life-span and quality-of-life
for patients with haemophilia had
improved steadily throughout the
early 1980s but the principal cause
of death remained intracranial
haemorrhage until the epidemic
of HIV infection due to contami-
nated factor concentrates. Infec-
tion with hepatitis C virus is
almost universal for patients trea-
ted with clotting factors before
1985. No curative treatment is
available for hepatitis C at pre-
sent. Knowledge of the transmis-
sion ofviruses in concentrates has
led to important developments in
processing techniques to elimi-
nate them. Recombinant technol-
ogy has produced factor VIII and,
more recently, factor IX concen-
trate which is likely to be very
safe. Development of inhibitors to
factor concentrates (especially
factor VIII) remains one of the
most serious complications of
haemophilia. The variety of treat-
ments available testifies to the lack
of a single universally efficacious
one. The use ofprophylactic treat-
ment has been conclusively de-
monstrated to result in a
preservation of joint function in
severely affected patients who
might otherwise develop signifi-
cant joint problems. The many
facets of the care of patients with
severe haemophilia, ranging from
dental care to genetic counselling,
can be advantageously co-ordi-
nated in a haemophilia compre-
hensive care centre.
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Haemophilia is an ancient disease. It neither selects nor spares any class or
ethnic group. As early as the fifth century AD, haemophilia was referred to in
the Babylonian Talmud.' A description of the disorder in the early 1 800s by the
American physician Otto,2 accurately described the pattern of inheritance. In
the late 1940s Pavlovsky' discovered that blood from one haemophilia sufferer
could correct the defect in another. It was surmised that the bleeding was due to
a lack of 'anti-haemophiliac factor' in the blood. The existence of two separate
forms of haemophilia was not inferred until 1952 when one type of haemophilia
was described lacking what we now know to be factor VIII and the other lacking
'plasma thromboplastin component', later called factor IX.4 The more common
of the two disorders, classical haemophilia or haemophilia A, has a prevalence of
1 in 10 000 and haemophilia B or Christmas disease has a prevalence of 1 in
50 000.
Genetics
Both haemophilia A and B are X-linked recessive disorders and therefore
occur almost exclusively in males. The sons of haemophilia patients will be
unaffected and all the daughters will be carriers. For carrier females with
normal partners, half their sons will have haemophilia and half their daughters
will be carriers.
The genes for both factors VIII and IX have been mapped to the distal end
of the long arm of the X chromosome, bands Xq28 and Xq27. 1, respectively.
The genetic code itself has been sequenced for both genes. The factor VIII
gene is very large, comprising 186kb of DNA with 9kb of exon (sequences of
coding DNA). The coding base consists of 26 exons. Over 80 different
mutations have been characterised5 and they include deletions, insertions and
point mutations. However, until recently, about 50% of severe haemophiliacs
had no detectable mutations.6'7 A novel form of mutation in which a very large
sequence of DNA becomes inverted, has now been shown to account for
almost all of these cases of severe haemophilia A.6-9 Within the factor VIII
gene there are two regions of coding DNA known as F8A and F8B. The
former has two copies which extend outside the factor VIII gene towards the
chromosomal telomere. This is the segment which is inverted (figure). The
factor IX gene is 34kb in length and the essential genetic information is
present in eight exons. Over 400 distinct mutations have been documented in
haemophilia B,'0 most of which impair the synthesis, secretion or stability of
factor IX. Interestingly, a significant number of both factor VIII and factor IX
gene mutations occur at CG dinucleotides."1 These mutations often involve
arginine residues at critical positions, resulting either in changes at the
molecules' functional sites or in inappropriate stop codons. About one-third
of patients with haemophilia have new mutations.'2
Using recent advances in genetics, it is possible to offer potential
haemophilia carriers accurate diagnoses in the great majority of cases. This
is particularly useful when assays of coagulation factors (phenotypic analysis)
give uncertain results. Once the defect is known (or if there is an informative
polymorphism of DNA to act as a marker), accurate and rapid antenatal
diagnosis can be carried out from about nine weeks gestation using chorionic
villous sampling.
Classification and clinical manifestations
Haemophilia is classified according to the baseline level of clotting factor.
Severely affected patients have < 1 % of normal factor levels, moderate
patients 1-4%, and mild 5-50%. Patients with severe haemophilia have
frequent and often severe bleeds while those with mild disease may be little
troubled by clinical manifestations. The complications usually associated with
haemophilia are listed in box 1 and an illustrative case history is presented in
box 2.
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Normal sequence
26 23 22 1
3' 3 O 5'
F8A F8A F8A
26 23 22 1
3 5
Mutated sequence
Figure 1 The normal factor VIII gene is
shown in part, together with the extragenic
copies of the F8A gene. In the mutated gene,
the breakpoint at intron 22 and the large
inverted sequence are depicted
Complications of
haemophilia
Bleeding complications
* haemarthrosis - spontaneous/
frequent and disabling in severe
haemophilia
* soft tissue haematomas
* intracranial haemorrhage
* excessive bleeding after surgery
(including dental surgery)
* haematuria, epistaxis (less comon)
* haemophiliac arthropathy and joint
deformity
Complications of treatment
* development of inhibitors
* thrombosis
Infective complications of treatment
* hepatitis C
* HIV
* hepatitis B
Psychosocial complications
* emotional problems of chronic
disease (especially teenagers)
* problems with schooling and
employment
Rare complications
* pseudotumours of bone
Box 1
Life-threatening complications
INTRACRANIAL HAEMORRHAGE
We know from the long established national Swedish register of causes of death,
that before 1920 the median life expectancy of a child with severe haemophilia
was about 11 years. Between 1921 and 1960 this figure gradually increased to
20-30 years. After the discovery of more specific and effective treatment for
bleeding episodes, median life expectancy rose to over 56 years between 1961
and 1980. Data from the Swedish registry show intracranial bleeding was the
single most common cause of death in this era and half the deaths were
preceded by recorded trauma."3 Bleeding elsewhere, if uncontrolled, may also
present a threat to life in the haemophilia patient but death from uncontrolled
mucosal or post-surgical bleeding should now be avoidable.
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
The recognition of AIDS in patients with haemophilia in 1982'4 marked a
reversal in the continuous improvement in life expectancy and quality of life
experienced in previous years. AIDS has now overtaken fatal intracranial
haemorrhage as the main cause of mortality in patients with severe haemophilia.
The majority of severely affected patients with haemophila treated before 1986
have been infected with HIV, and many who were infected in the early 1980s
have already died of AIDS-related illnesses. In the UK from 1985 - 92, 85% of
deaths in seropositive patients were due to HIV infection.15 There is, at present,
no curative treatment and care is usually undertaken jointly by haemophilia and
HIV specialists.
HEPATITIS
By 1972 it was recognised that clotting factor concentrate could transmit
hepatitis. 16 Vaccination against hepatitis A and B is now universal practice and it
is hepatitis C which currently causes most anxiety.17 Before 1986 almost all
patients given clotting factor concentrates were infected with this virus. The
majority of infected patients develop some evidence of disease ranging from
mild chronic active hepatititis to cirrhosis but so far few have developed hepatic
failure and hepatocellular carcinoma. Most remain asymptomatic and may
never develop any clinical problems. About 10% of patients may develop liver
failure after 20 years or more of infection and co-infection with HIV may
accelerate this process18, as may alcohol abuse. Transmission of hepatitis C to
sexual partners is an infrequent occurrence.
Medical treatment is of limited efficacy. Alpha-interferon is the only licensed
agent but may help only 10-20% of patients to normalise liver function tests
over a sustained period. Results are, if anything, less encouraging for those with
haemophilia than for other groups'9. The reasons for this are uncertain but may
include associated HIV infection, infections with more than one strain of
hepatitis C virus and the duration of infection which in all cases will be greater
than 10 years and may be as much as 30 years. The difficulties of liver
transplantation are compounded by re-infection of the new liver with hepatitis
C after the transplant and most centres are reluctant to offer transplantation for
patients infected with HIV who are already immunosuppressed.
DEVELOPMENT OF INHIBITORS
The development of inhibitory antibodies to factor VIII and factor IX poses a
very difficult problem in the clinical management of haemophilia. Patients
whose haemophilia is due to deletions (especially in haemophilia B) or
nonsense mutations (and who therefore have no native protein) are more likely
to form inhibitors to either factor VIII5 or IX.
The strength of an inhibitor is measured by its ability to 'neutralise' factor
VIII or IX activity in in vitro clotting assays and is expressed in Bethesda units.
Inhibitors may be weak or potent, transient or persistent. They are thought to
affect 10 - 20% of patients with haemophilia A"0 but rarely occur in haemophilia
B. Close surveillance of patients receiving newer factor concentrates, both high-
purity and recombinant, has detected more frequent inhibitor development in
some studies and led to fears that inhibitor formation might be increased in
patients using these concentrates. One prospective study has revealed little
difference between patient groups2' and sequential studies designed to detect
the incidence of inhibitors in previously untreated patients have highlighted the
importance of transient inhibitors and provided reassurance with regard to
inhibitor development and recombinant factor VIII."2 Differences in study
design and frequency of assay may account for discrepant findings'3.
Although the transient nature of many inhibitors is reassuring, on one level it
creates difficulties with regard to the evaluation of immune tolerance regimes
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Illustrative case history
A man, now aged 35. Born with severe
haemophilia A but no family history.
Recurrent severe joint bleeds in elbow
(target joint) and other joints.
Commenced on home treatment.
Severity of bleeding made prophylactic
treatment desirable as already some
degree of deformity was clinically
demonstrable in the elbow and knee.
Some bleeds required admission for
bed rest and eight-hourly treatment.
Insufficient amount of NHS factor
VIII available to meet requirements of
prophylaxis in the 1970s. Therefore,
commenced on commercial
concentrate.
Coped well socially, failed to
manifest typical teenage 'refusal' of
chronic disease. Highly intelligent with
good progress academically. University
education undertaken, leading to
successful business career.
Frequency of bleeding diminished in
1980s. No inhibitors. Excellent quality
of life attained.
1978: hepatitis B
1986: confirmed HIV antibody
positive
1991: confirmed hepatitis C antibody
positive
Remained well despite 'transaminitis'
working full time and receiving 'on
demand' treatment. Took part in
prospective study of interferon therapy
for hepatitis C infection but withdrew
because of side-effects. Bleeding
episodes infrequent, no HIV-related
illness
1995: episode of fulminant hepatic
failure followed by good recovery
with medical treatment.
Should he be offered a liver transplant?
Box 2
for the treatment of inhibitors. Immune tolerance induction involves the daily
administration of clotting factor, often with immunomodulatory drugs. This
approach has been shown to be most successful when administered as soon as
inhibitors are detected. Inevitably this means some patients will be treated for a
problem which would have resolved spontaneously. However, the potential
seriousness of a high-titre inhibitor cannot be over-estimated. Treatment
strategies vary and details are beyond the scope of this article, but outlines are
given in box 3.
Treatment
The treatment options currently open to haemophiliacs are given in box 4.
BLOOD PRODUCTS
Treatment of haemophilia has evolved from 'the shadows towards the light'31
over the past 25 years. Initially, fresh frozen plasma was the only product
available for treatment of bleeding episodes and huge volumes were required.
The discovery that the 'antihaemophilic globulin' was concentrated in
cryoprecipitate 2 helped pave the way to the large scale production of crude
lyophilised cryoprecipitate concentrates. With chromatographic purification,
intermediate purity concentrates of factors VIII and IX became the mainstay of
treatment of factor VIII deficiency through the 1970s and 80s and have been
safe with respect to HIV and hepatitis C transmission, since effective donor
selection and viral inactivation have been available.
There has been some concern that intermediate purity factor VIII
concentrates are associated with immunosuppressive effects.3 These effects
have been attributed to the non-factor VIII plasma proteins in the concentrate
and have contributed to the drive to use high-purity products. High-purity
factor VIII concentrates have an increased concentration of factor VIII and are
free from other plasma proteins, although albumin is added after processing to
stabilise the product. They are recommended34 for the treatment of patients
infected with HIV and are increasingly being used for all patients in the
developed world.
For patients with factor IX deficiency, intermediate purity factor IX is
unacceptably thrombogenic, especially in the context of orthopaedic surgery.
Thrombotic potential is probably due to contaminating activated coagulation
factors. High-purity factor IX is now available and has replaced the
intermediate purity product in the UK. Inhibitors of fibrinolysis should not
be used in conjunction with factor IX therapy.
The dose of factor VIII concentrate administered is based on the calculation
that 1 international unit (IU) of factor VIII per kg of body weight will increase
the plasma level by 0.02 IU/ml. A level of 0.5 IU/ml is considered necessary for
treating most serious muscle or joint bleeds, but for major surgery or head
injuries a level of 1 IU/ml (ie, 100% of normal levels) may be required. The
half-life of factor VIII is eight hours and therefore 8- 12 hourly dosing
schedules are needed. For factor IX the half-life is longer (approximately 18
Treatment of patients with inhibitors to factor VIII or IX
Principle Method Reference
Acute treatments
* swamp inhibitor High dose factor concentrate (for 23
low titre inhibitor)
* alternative species factor VIII Porcine factor VIII 24
* bypass 'block' in clotting cascade Infusion of prothrombin complex 25, 26, 27
concentrates or activated prothrom-
bin complex concentrates. Infusion
of activated factor VII
Chronic treatments (may be commenced in acute situation in addition to above)
* induce immune tolerance Continuous factor VIII infusion 28
and combination regimens
* immune suppression* Cyclophosphamide
* removal of inhibitor Plasma exchange/pheresis, protein 29, 30
A column immunoadsorbtion
*Usually used in conjunction with other modalities of therapy, most notably in the
Malmo regime2
Box 3
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Haemophilia: treatment
options
* factor replacement: intermediate
purity, high purity factor VIII; high
purity factor IX; recombinant factor
VIII; (recombinant factor IX);
porcine factor VIII; activated
prothrombin complex concentrates;
factor VIIa (plasma derived or
recombinant)
* release of endogenous stores:
desmopressin (for mild haemophilia
A only)
* clot stabilisation: tranexamic acid,
epsilon amino-caproic acid (useful
adjunctive therapy in mild
haemophilia)
* topical applications: topical
thrombin (of limited use in gingival/
mucosal bleeding)
Box 4
hours in vivo) and once-daily treatment is sufficient except for the most serious
bleeds. For factor IX, 1 IU/kg body weight will increase the plasma level by
0.01 IU/ml.
Measurement of peak and trough levels should be carried out to guide
treatment and an inhibitor screen should be performed before planned surgery.
In some situations, such as replacement therapy for surgery, the use of
continuous infusion of factor VIII is advantageous as lower doses are required
and troughs are avoided.35
NON-BLOOD PRODUCT HAEMOSTATIC TREATMENT
The hormone desmopressin is capable of raising the plasma level of factor VIII,
two- or three-fold.36 It is thought to work by releasing stores of factor VIII from
the endothelium; therefore, tachyphylaxis occurs after several doses until
reaccumulation of stores can take place. It is only useful in patients with
measurable factor VIII (ie, mild to moderate haemophilia) and is usually given
by slow intravenous infusion at a dose of 0.3 pg/kg. Not all patients respond
predictably and factor VIII levels are checked post-infusion to ensure that a
satisfactory response has occurred. It is now available (on a named patient
basis) for subcutaneous injection and this route greatly enhances its
acceptability in small children. Because of the associated side-effects of fluid
retention and hypertension, the use of desmopressin is not recommended in
patients under two or over 60 years of age. It should not be used in patients with
known ischaemic heart disease or those who have sustained a severe bleed or
injury. Administration of desmopressin is associated with activation of
fibrinolysis and, in general, the concomitant use of a fibrinolytic inhibitor,
such as tranexamic acid or epsilon amino-caproic acid is recommended.
Fibrinolytic inhibitors can also be usefully administered in conjunction with
factor VIII but anti-fibrinolytic therapy is contra-indicated in the presence of
haematuria and is not used with factor IX concentrate.
ADMINISTRATION OF TREATMENT
Treatment can be administered 'on-demand' or prophylactically. Currently the
majority of haemophilia treatment is administered on-demand and this can be
done either in the hospital or the home/community setting. For severe
haemophilia, home treatment is now established as safe and effective and, in
general, is acceptable to this well-motivated group of patients and families.37
For patients with moderate or mild haemophilia, on demand treatment in
hospital is most appropriate. It should be remembered that even mild
haemophilia may result in bleeding severe enough to necessitate vigorous
treatment and hospital admission. Patients and families are encouraged always
to contact the haemophilia centre for advice.
PROPHYLAXIS
The obvious efficacy of treatment and the convenience of use of factor
concentrates has encouraged the concept of prophylactic treatment. Patients
with severe haemophilia experience bleeding episodes 30 times a year or more.
The potential for irreversible joint damage is graphically demonstrated in some
older patients who have survived life-threatening bleeds but whose degree of
permanent joint deformity is testimony to the need for primary prevention ofjoint bleeding. This has only been possible since the manufacture of stable factor
concentrates in sufficient amounts was achieved in the 1 970s, although Sweden
was one of the first countries to institute a comprehensive programme of
prophylaxis beginning as early as 1958.38 The aim of prophylaxis is to convert
severe haemophilia to mild/moderate disease by administering sufficient factor
VIII, on a three times a week basis (or factor IX twice a week) to keep trough
levels offactors above 1%. Reporting on the results ofprophylaxis in a population
of 60 severe haemophiliacs, the Malmo group noted older patients had minimaljoint deformity.38 For younger patients (<17 years) the majority had no
detectable joint damage and all 60 patients had good quality of life. It is clear thatjoint disease is preventable even in severe haemophilia. The Swedish group
commence prophylaxis between the ages ofone and two years,38 necessitating the
insertion of indwelling venous access with all its attendant problems.
VIRUSES AND CONCENTRATES
It had been recognised since 1972 that hepatitis B and non-A, non-B hepatitis
could be transmitted by clotting factor concentrates'6. With the recognition that
concentrate transmitted HIV infection to haemophilia patients, efforts to
produce virally inactivated concentrates were intensified.3' These have
culminated in the production of a generation of products which are safe and
free from lipid-coated viruses. Some products have undergone double viral
Haemophilia
inactivation steps - for example, dry heating or ultrafiltration may be combined
with a chemical inactivation step such as the use of solvent detergent processes
or sodium thiocyanate'1. Thanks to these measures there have been no cases of
seroconversion from HIV, hepatitis B or C recorded in the UK since 1986.
Despite this significant achievement, caution is warranted because documented
transmission of hepatitis A and parvovirus B19 have occurred in Europe39'40 and
this indicates that non-lipid coated viruses can escape inactivation procedures.
RECOMBINANT FACTOR VIII (rVIII)
Factor VIII derived by recombinant technology is now available in the UK and
should carry no viral risk. Manufacturers, however, add small amounts of
human albumin in order to stabilise their products. A concentrate free of all
human protein is now undergoing clinical trials, as is a recombinant factor IX
concentrate.
The administration of care
THE COMPREHENSIVE CARE CENTRE (CCC) CONCEPT
Although treatment of haemophilia may be seen in the narrow context of
administration of haemostatic medications as outlined above, care of the
haemophilia patient is a much broader issue. The Department of Health
recently recognised this by publishing a Health Service Guidelines document.4"
This firmly establishes the concept of a comparatively small number of
specialised units, able to provide the facilities to deal with the broad range of
problems and complications which can occur in patients with haemophilia. The
protocol requires the establishment of a co-ordinated network of collaboration
with specialists in rheumatology, orthopaedics, HIV and hepatitis, dentistry,
social work, physiotherapy and occupational health. Special arrangements must
be in place to ensure that children receive both expert haemophilia and
paediatric care, usually through joint clinics. CCC's must operate a 24-hour
service for patients (and staff in other centres) for advice and treatment.
Establishing and co-ordinating community and prophylactic care is usually
the responsibility of the CCC but other hospitals may become involved as
haemophilia centres. These centres may also offer a wide range of services but
usually rely on a CCC for some aspects of specialist care such as diagnosis and
the counselling of carriers and patients with regard to genetics and antenatal
diagnosis. The effect of these arrangements has been to limit and regulate the
'market' in healthcare (created by the new National Health Service reforms) for
the benefit of the haemophilia community.
COMMUNITY CARE
With the growth of home treatment and prophylactic treatment programmes,
patients with haemophilia and their families are spending less time in hospital,
both as out- and in-patients. This welcome development is not new42 but has
become more widespread. It has meant that some aspects of care and follow-up
normally attended to in hospital are now carried out in the community by a co-
ordinator42 (usually a haemophilia nurse specialist) who organises aspects such
as home treatment, prophylaxis and vaccination programmes. The haemophilia
nurse specialist may undertake the continuing education of patients and their
families and may also visit schools and community groups when required. The
expansion in the role and responsibility43 of the haemophilia nurse specialist is a
necessary and welcome development in the improvement of services for patients
with haemophilia.
The future
Attention must remain focused on blood product safety to protect the current
cohort of children. It is important that we can reassure their parents that they
will not suffer from transmissible disease and the use of factor VIII derived by
recombinant technology is likely to replace biologically derived factor VIII in
this age group and in previously untreated patients.
Prophylaxis will be more widely used as viral safety is ensured and cost
effectiveness becomes evident. We should aspire to raising the median survival
of patients with haemophilia to approach that of the general population and
simultaneously to improve their quality of life and freedom from disabilty.
It is likely to be some years before gene therapy becomes a reality since there
are many problems still to solve. The ability to create a low resting level of factor
VIII or IX by the introduction of functional cells whose survival and activity can
be ensured over a period of months or years, would transform the care of
haemophilia even if a genetic cure is a more distant goal.
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